SCHEMBL4157745

SCHEMBL4157745

O=c1[nH]c(=O)n(Cc2ccc(F)cc2)cc1-c1ccco1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.54
KDM4E B2RXH2 4/20 0.54
MAPK1 P28482 1/20 0.54
HPGD P15428 3/20 0.43
MEN1 O00255 5/20 0.42
KMT2A Q03164 5/20 0.42
NPSR1 Q6W5P4 2/20 0.42
HSD17B10 Q99714 2/20 0.42
PRNP P04156 1/20 0.42
MAPK10 P53779 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
PKM P14618 1/20 0.41
P2RY2 P41231 1/20 0.40
F2 P00734 1/20 0.39
HTT P42858 1/20 0.39
GAA P10253 1/20 0.39
TSHR P16473 1/20 0.39
CASP1 P29466 1/20 0.39
POLB P06746 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4167785 0.84 KDM4E (0.48) ALDH1A1KDM4EMAPK1HPGDMEN1
SCHEMBL4158442 0.77 KDM4E (0.48) ALDH1A1KDM4EMAPK1HPGDMEN1
SCHEMBL4174262 0.75 P2RY2 (0.44) ALDH1A1KDM4EMEN1KMT2APKM
SCHEMBL4173284 0.75 HPGD (0.43) ALDH1A1HPGDMEN1KMT2AHSD17B10
SCHEMBL5123986 0.73 HPGD (0.72) MAPK1HPGD
SCHEMBL12501006 0.73 KMT2A (0.66) ALDH1A1HPGDMEN1KMT2A
SCHEMBL4176930 0.73 TYMP (0.48) HPGDMEN1KMT2AHSD17B10
SCHEMBL12501014 0.73 HPGD (0.48) HPGDMEN1KMT2A
SCHEMBL4165444 0.72 ALDH1A1 (0.51) ALDH1A1KDM4EMAPK1HPGDMEN1
SCHEMBL4170112 0.71 KMT2A (0.53) ALDH1A1KDM4EMAPK1HPGDMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090149485-A1 PYRIMIDINEDIONES AS TYROSINE KINASE INHIBITORS JUBILANT BIOSYS LIMITED (IN) 2009-06-11 US claimed
WO-2007122634-A2 PYRIMIDINEDIONES AS TYROSINE KINASE INHIBITORS JUBILANT BIOSYS LIMITED (IN) 2007-11-01 WO claimed
US-20090149485-A1 PYRIMIDINEDIONES AS TYROSINE KINASE INHIBITORS JUBILANT BIOSYS LIMITED (IN) 2009-06-11 US disclosed
US-20090149485-A1 PYRIMIDINEDIONES AS TYROSINE KINASE INHIBITORS JUBILANT BIOSYS LIMITED (IN) 2009-06-11 US disclosed
US-20090149485-A1 PYRIMIDINEDIONES AS TYROSINE KINASE INHIBITORS JUBILANT BIOSYS LIMITED (IN) 2009-06-11 US disclosed
WO-2007122634-A2 PYRIMIDINEDIONES AS TYROSINE KINASE INHIBITORS JUBILANT BIOSYS LIMITED (IN) 2007-11-01 WO disclosed
WO-2007122634-A2 PYRIMIDINEDIONES AS TYROSINE KINASE INHIBITORS JUBILANT BIOSYS LIMITED (IN) 2007-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149485-A1 PYRIMIDINEDIONES AS TYROSINE KINASE INHIBITORS TK1, LCK, FYN ALDH1A1 1813/4885KDM4E 2284/4885MAPK1 107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.